Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer
Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer
Recruiting · NCT07860047 · Registry updated 2026-10-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2026-10-06 | NCT07860047 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University Hospital Tuebingen | 123 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| CCU Transltional Immunolgy, University Hospital Tübingen | Tübingen | Germany | 1 |
| Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin - Studienzentrale Onkologie | Berlin | Germany | 1 |
| NCT Studienzentrale; Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg | Heidelberg | Germany | 1 |
| Universitätsklinikum Essen, Abteilung Urologie | Essen | Germany | 1 |